These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Real-time asthma outreach reduces excessive short-acting β2-agonist use: a randomized study. Zeiger RS; Schatz M; Li Q; Solari PG; Zazzali JL; Chen W J Allergy Clin Immunol Pract; 2014; 2(4):445-456, 456.e1-5. PubMed ID: 25017534 [TBL] [Abstract][Full Text] [Related]
23. Overprescription of short-acting β2 agonists: reflections from the SABINA study in Brazil. Antila MA; Souza-Machado A; Gregório MG; Cruz ÁA; Angelini L; Beekman MJHI; Zonzin GA; Rabahi MF J Bras Pneumol; 2024; 50(1):e20230174. PubMed ID: 38422337 [TBL] [Abstract][Full Text] [Related]
24. It is time to change the way we manage mild asthma: an update in GINA 2019. Muneswarao J; Hassali MA; Ibrahim B; Saini B; Ali IAH; Verma AK Respir Res; 2019 Aug; 20(1):183. PubMed ID: 31412856 [TBL] [Abstract][Full Text] [Related]
25. Health-care utilization and costs with fluticasone propionate and fluticasone propionate/salmeterol in asthma patients at risk for exacerbations. Hagiwara M; Delea TE; Stanford RH Allergy Asthma Proc; 2014; 35(1):54-62. PubMed ID: 24433597 [TBL] [Abstract][Full Text] [Related]
26. Overuse of short-acting β Nwaru BI; Ekström M; Hasvold P; Wiklund F; Telg G; Janson C Eur Respir J; 2020 Apr; 55(4):. PubMed ID: 31949111 [TBL] [Abstract][Full Text] [Related]
27. Overprescription of short-acting β Al-Jahdali H; Wali S; Albanna AS; Al Harbi A; Allehebi R; Arwadi A; Dahan T; Fattouh M; Hamza E; Beekman M Clin Respir J; 2022 Dec; 16(12):812-825. PubMed ID: 36279888 [TBL] [Abstract][Full Text] [Related]
28. Does pre-hospital telephone communication with a clinician result in more appropriate medication administration by parents during childhood asthma exacerbations? Garro AC; Fearon D; Koinis-Mitchell D; McQuaid EL J Asthma; 2009 Nov; 46(9):916-20. PubMed ID: 19905918 [TBL] [Abstract][Full Text] [Related]
29. Prescription patterns in asthma patients initiating salmeterol in UK general practice: a retrospective cohort study using the General Practice Research Database (GPRD). DiSantostefano RL; Davis KJ Drug Saf; 2011 Jun; 34(6):511-20. PubMed ID: 21585223 [TBL] [Abstract][Full Text] [Related]
30. Asthma-Related Health Outcomes Associated with Short-Acting β Bloom CI; Cabrera C; Arnetorp S; Coulton K; Nan C; van der Valk RJP; Quint JK Adv Ther; 2020 Oct; 37(10):4190-4208. PubMed ID: 32720299 [TBL] [Abstract][Full Text] [Related]
31. The impact of inappropriate use of short acting beta agonists in asthma. FitzGerald JM; Tavakoli H; Lynd LD; Al Efraij K; Sadatsafavi M Respir Med; 2017 Oct; 131():135-140. PubMed ID: 28947020 [TBL] [Abstract][Full Text] [Related]
33. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma. Blanchette CM; Culler SD; Ershoff D; Gutierrez B Clin Ther; 2009 Nov; 31(11):2574-83. PubMed ID: 20110003 [TBL] [Abstract][Full Text] [Related]
34. Healthcare costs associated with short-acting β Attar-Zadeh D; Capstick T; Leese D; Arnetorp S; Rapsomaniki E; Da Costa KP; Maslova E; Xu Y; Gibson D; Quint JK BJGP Open; 2023 Sep; 7(3):. PubMed ID: 36759020 [TBL] [Abstract][Full Text] [Related]
35. Identifying the drivers of patients' reliance on short-acting β2-agonists in asthma. Blakeston S; Harper G; Zabala Mancebo J J Asthma; 2021 Aug; 58(8):1094-1101. PubMed ID: 32469667 [TBL] [Abstract][Full Text] [Related]
36. High Use of SABAs is Associated with Higher Exacerbation Rate in Dutch Patients with Asthma. Baron AJ; Flokstra-de Blok BMJ; Kerstjens HAM; Koopmans-Klein G; Price DB; Sellink AA; Tsiligianni I; Kocks JWH J Asthma Allergy; 2021; 14():851-861. PubMed ID: 34285512 [TBL] [Abstract][Full Text] [Related]
37. Reducing short-acting beta-agonist overprescribing in asthma: lessons from a quality-improvement prescribing project in East London. De Simoni A; Hajmohammadi H; Pfeffer P; Cole J; Griffiths C; Hull SA Br J Gen Pract; 2022 Jun; 72(722):e619-26. PubMed ID: 35995577 [TBL] [Abstract][Full Text] [Related]
38. Economic Consequences of the Overuse of Short-Acting ß-Adrenergic Agonists in the Treatment of Asthma in Spain. Valero A; Molina J; Nuevo J; Simon S; Capel M; Sicras-Mainar A; Sicras-Navarro A; Plaza V J Investig Allergol Clin Immunol; 2023 Apr; 33(2):109-118. PubMed ID: 34825651 [TBL] [Abstract][Full Text] [Related]
39. Landscape of short-acting beta-agonists (SABA) overuse in Europe. de Las Vecillas L; Quirce S Clin Exp Allergy; 2023 Feb; 53(2):132-144. PubMed ID: 36468654 [TBL] [Abstract][Full Text] [Related]
40. High oral corticosteroid exposure and overuse of short-acting beta-2-agonists were associated with insufficient prescribing of controller medication: a nationwide electronic prescribing and dispensing database analysis. Sá-Sousa A; Almeida R; Vicente R; Nascimento N; Martins H; Freitas A; Fonseca JA Clin Transl Allergy; 2019; 9():47. PubMed ID: 31559008 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]